Results 21 to 30 of about 186,128 (186)

Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up [PDF]

Clinical Ophthalmology
Taras B Kustryn, Oleg S Zadorozhnyy, Illia O Nasinnyk, Alla O Nevska, Kseniia V Troianovska, Nataliya V Pasyechnikova, Andrii R Korol Laser Microsurgery Department, The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of ...
Kustryn TB, Zadorozhnyy OS, Nasinnyk IO, Nevska AO, Troianovska KV, Pasyechnikova NV, Korol AR   +6 more
doaj   +2 more sources

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration [PDF]

Ophthalmology, 2018
Rufino Silva, András Berta, Michael Larsen, Wayne Macfadden, Chrystel Feller, Jordi Monés   +5 more
openaire   +4 more sources

External Limiting Membrane Disruption Predicts Long-Term Outcome in Strict Treat-And-Extend Regimen in Neovascular Age-Related Macular Degeneration

Frontiers in Medicine, 2021
The use of anti-vascular-endothelial growth factor agents for neovascular age-related macular degeneration (nAMD) in different treatment schemes is widely common in clinical practice.
Laura Hoffmann, Katja Hatz, Katja Hatz
doaj   +1 more source

Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration

BMC Ophthalmology, 2020
Background To evaluate the three-year outcome after intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD). Methods Forty-nine treatment-naïve nAMD patients (50 eyes) were enrolled in this prospective study.
Kanako Itagaki, Tetsuju Sekiryu, Akihito Kasai, Yukinori Sugano, Masashi Ogasawara, Masaaki Saito   +5 more
doaj   +1 more source

Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports [PDF]

, 2020
Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these ...
Avery, Bergvall, Caballero, Campochiaro, Cutroneo, de Jong, De Rossi, Evans, Ferrara, Ferrara, Kumar, Lim, Lindquist, McColl, Meyer, Robinson, Sanchez, Sharma, Sheikh, Simó, Steen, Storkebaum, Sultana, Thulliez, Tian, Trifirò, Ueta, Wong, Yasuhara, Ylä-Herttuala, Zachary   +30 more
core   +4 more sources

GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration [PDF]

, 2016
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the ...
Altay, Lebriz, Baird, Paul N, Burdon, Kathryn Penelope, Chen, John, de Jong, Eiko K, den Hollander, Anneke I, Fauser, Sascha, Guymer, Robyn H, Hoyng, Carel B, Koenekoop, Robert K, Lores-Motta, Laura, Lu, Yi, MacGregor, Stuart, Montgomery, Grant W, Muether, Philipp, Omar, Amer, Riaz, Moeen, Richardson, Andrea J, Schick, Tina, Smailhodzic, Dzenita, van Asten, Freekje   +20 more
core   +5 more sources

Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration [PDF]

, 2020
Purpose: This study describes the long-term visual and anatomic outcomes of antivascular endothelial growth factor (VEGF) treatment using a treat and extend dosing regimen.
G Garg, Pooja, K Gill, Manjot, Lee, Andy, Mirza, Rukhsana, T Lyon, Alice   +4 more
core   +3 more sources

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration

International Journal of Retina and Vitreous, 2021
Purpose To investigate the visual and anatomical outcomes associated with treat-and-extend (TAE) regimen of intravitreal (IVT) aflibercept in eyes with treatment naïve neovascular age-related macular degeneration (nvAMD).
Mohamed Kamel Soliman, Nicolas Tuli, Thomas K. Lee, William A. Britton, Raman Tuli   +4 more
doaj   +1 more source

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting

BMC Ophthalmology, 2017
Background To evaluate the clinical effectiveness and analyze the outcomes of a treat-and-extend (T&E) treatment regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life clinical settings over the first 2 years (24 months) of
Athanasios Vardarinos, Nitin Gupta, Raazia Janjua, Abigail Iron, Theo Empeslidis, Konstantinos T. Tsaousis   +5 more
doaj   +1 more source

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Ophthalmology and Therapy, 2020
Aims To report the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and reading performance (reading acuity and maximum reading speed (MRS) using the MNREAD test) between baseline and 24 months in ...
Praveen J. Patel, Hari Jayaram, Maria Eleftheriadou, Clara Vazquez-Alfageme, Niaz Islam, Gary S. Rubin, Bishwanath Pal, Peter K. Addison, Robin Hamilton, Simona Degli Esposti   +9 more
doaj   +1 more source